2016-Present
Start of a Global Business
Opened a new SEANOL® production facility and R&D center in Jeju Novel Technology Industry Complex.
Phase I Product lineup for SEANOL®-based cosmeceuticals and personal hygiene products was established.
Signed an agreement with a Beijing-based corporation for investing KRW 170 billion for distributing and marketing SEANOL®-based products in China.
SEAPOLYNOL® was authorized as an NFI (Novel Food Ingredient) for legal marketing throughout EU countries.
Biochemical mechanism of SEANOL®'s supper-antioxidant effect was revealed.
Started global supply of research-grade high-purity eckols.
Phase I Product lineup for SEANOL®-based nutraceuticals was established.
2013-2015
Entering Pharmaceutical Development
2013
PH100 was approved as an IND (Investigational New Drug) by the US FDA.
2014
Phase I clinical study for PH100 was successfully completed.
2015
PH100 Technology was licenced out for Phase II and further development.
The cellular mechanism of SEANOL®'s anti-neurodegenerative effect was revealed.
2010-2012
Technological Maturation
2010
The Seanol Science Center website was published.
The Seanol Research Expert Group was organized for various research in SEANOL®'s bioactivites.
2011
Prototypical lineup of SEANOL®-based personal hygiene products was developed for pre-marketing.
2012
SEAPOLYNOL® was approved as a Health-Functional Food Ingredient by the Korean FDA.
Corporate name was changed to BOTAMEDI Inc.
2007-2009
Technological Growth
2007
Opened the first SEANOL® production facility in Jeju Biotechnology center.
2008
SEANOL® Ecklonia cava extract was authorized as an NDI(New Dietary Ingredient) by the US FDA for legal interstate marketing in the US.
2009
Prototypical lineup of SEANOL®-based nutraceutical products was developed for pre-marketing.
2001-2006
An Innovative Start
Established basic chemistry and biochemistry of SEANOL®.
Discovered the anti-inflammatory effect of SEANOL® in macrophages.
Discovered the cognitive improvement effect of SEANOL® in a mouse model.
Developed the global standard of SEANOL® and its manufacturing technology.
Discovered the anti-diabetic effect of SEANOL® in a mouse model.
Received investment of USD 60 million from BMRG in Hong Kong.
Received investment of KRW 500 million from the Korean Development Bank.
Designated as "Innobiz Corperation" and "Growth-Promising Small Corperation."
Discovered the anti-cancer effect of SEANOL® in a mouse model.
Corperate Establishment.
(LIVECHEM INC.)